250 related articles for article (PubMed ID: 17259791)
1. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.
Negro R; Formoso G; Hassan H
J Endocrinol Invest; 2006 Dec; 29(11):957-61. PubMed ID: 17259791
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
[TBL] [Abstract][Full Text] [Related]
4. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance.
Makita S; Abiko A; Naganuma Y; Moriai Y; Nakamura M
Metabolism; 2008 Oct; 57(10):1473-8. PubMed ID: 18803955
[TBL] [Abstract][Full Text] [Related]
5. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
[TBL] [Abstract][Full Text] [Related]
6. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
[TBL] [Abstract][Full Text] [Related]
7. Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.
De Luis DA; Conde R; Gonzalez Sagrado M; Aller R; Izaola O; Perez Castrillon JL; Romero E; Castro MJ
Eur Rev Med Pharmacol Sci; 2010 Sep; 14(9):759-63. PubMed ID: 21061834
[TBL] [Abstract][Full Text] [Related]
8. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.
Shimabukuro M; Tanaka H; Shimabukuro T
J Hypertens; 2007 Apr; 25(4):841-8. PubMed ID: 17351377
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
Mori H; Okada Y; Arao T; Nishida K; Tanaka Y
Adv Ther; 2012 Jul; 29(7):635-44. PubMed ID: 22821644
[TBL] [Abstract][Full Text] [Related]
10. [The role of telmisartan in the treatment of metabolic syndrome].
Mychka VB; Duishvili DE; Mamyrbaeva KM; Masenko VP; Chazova IE
Ter Arkh; 2006; 78(8):63-6. PubMed ID: 17078220
[TBL] [Abstract][Full Text] [Related]
11. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome.
Kagota S; Tada Y; Nejime N; Nakamura K; Kunitomo M; Shinozuka K
Can J Physiol Pharmacol; 2011 May; 89(5):355-64. PubMed ID: 21619437
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats.
Younis F; Oron Y; Limor R; Stern N; Rosenthal T
Metabolism; 2012 Feb; 61(2):164-74. PubMed ID: 21820685
[TBL] [Abstract][Full Text] [Related]
14. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Pershadsingh HA
Int J Biochem Cell Biol; 2006; 38(5-6):766-81. PubMed ID: 16298156
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Kishi T; Hirooka Y; Konno S; Sunagawa K
J Hypertens; 2012 Aug; 30(8):1646-55. PubMed ID: 22728908
[TBL] [Abstract][Full Text] [Related]
16. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K
Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143
[TBL] [Abstract][Full Text] [Related]
17. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Bahadir O; Uzunlulu M; Oguz A; Bahadir MA
Hypertens Res; 2007 Jan; 30(1):49-53. PubMed ID: 17460371
[TBL] [Abstract][Full Text] [Related]
18. Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients.
de Luis DA; Conde R; González-Sagrado M; Aller R; Izaola O; Dueñas A; Pérez Castrillón JL; Romero E
Nutr Hosp; 2010; 25(2):275-9. PubMed ID: 20449538
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients.
Usui I; Fujisaka S; Yamazaki K; Takano A; Murakami S; Yamazaki Y; Urakaze M; Hachiya H; Takata M; Senda S; Iwata M; Satoh A; Sasaoka T; Ak ND; Temaru R; Kobayashi M
Diabetes Res Clin Pract; 2007 Aug; 77(2):210-4. PubMed ID: 17240472
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
